Body Integrity Dysphoria and Gender Dysphoria are often compared because both involve distress around the relation between self and body. The comparison is clinically relevant, but it becomes misleading when ICD-11 and DSM-5-TR are treated as if they were saying the same thing.
In the bioethics literature on Body Integrity Dysphoria, one comparison appears again and again. BID is placed beside Gender Dysphoria because both conditions involve a persistent conflict between the body as physically configured and the body as experienced by the person. In both, the distress can be chronic. In both, the requested response may involve bodily modification. In both, the intervention, once surgical, can be irreversible.
That comparison is useful because it exposes asymmetry in medicine. One form of self-body conflict has developed recognised pathways of care. The other remains largely without a pathway, without specialist provision, and without professional agreement on what an appropriate clinical response would look like.
The comparison also has limits. BID and Gender Dysphoria do not sit in the same diagnostic, institutional, or evidential position. Treating them as equivalent weakens the argument. Refusing the comparison entirely avoids the issue: how medicine decides which forms of bodily incongruence deserve structured care.
The diagnostic starting point
The first distinction is terminological and classificatory.
In the DSM-5-TR, the relevant diagnosis is Gender Dysphoria. The word dysphoria is central because the DSM diagnosis requires more than gender incongruence. It requires marked incongruence between experienced or expressed gender and assigned gender, lasting at least six months, together with clinically significant distress or impairment. In the DSM framework, distress gives the diagnosis its psychiatric form.
ICD-11 takes a different route. It uses the category Gender Incongruence, placed under Conditions Related to Sexual Health, rather than under mental disorders. WHO made this move to reduce the pathologisation of trans and gender-diverse identities while preserving a diagnostic route for access to gender-affirming healthcare. In ICD-11, the emphasis falls on marked and persistent incongruence between experienced gender and assigned sex, often linked to a desire for social, hormonal, surgical, or other forms of transition. Gender-variant behaviour alone is insufficient.
This distinction is important because Gender Dysphoria and Gender Incongruence are not interchangeable labels. DSM-5-TR frames the clinical diagnosis through distress or impairment. ICD-11 frames gender incongruence as a sexual health-related condition, deliberately moved away from the mental disorder chapter. The older language of transsexualism and gender identity disorder belongs to previous classificatory systems. In ICD-11, that older diagnostic architecture has been replaced.
BID occupies a different place again. ICD-11 places Body Integrity Dysphoria under mental, behavioural, and neurodevelopmental disorders. Its central clinical feature is dysphoria in relation to the current, non-disabled body configuration. ICD-11 describes BID as an intense and persistent desire to become physically disabled in a significant way, usually beginning by early adolescence, accompanied by persistent discomfort or intense feelings of inappropriateness concerning the present body. The diagnosis also requires harmful consequences, such as preoccupation interfering with life or attempts to become disabled placing health or life in danger.
So the word dysphoria carries different weight in the two cases. In DSM-5-TR, Gender Dysphoria names distress associated with gender incongruence. In ICD-11, gender-related diagnosis shifts toward incongruence and away from psychiatric dysphoria. BID, by contrast, enters ICD-11 precisely as Body Integrity Dysphoria. The discomfort, inappropriateness, and distress attached to the non-disabled body are part of the diagnostic core.
What the comparison gets right
At the level of clinical phenomenology, the parallel remains difficult to dismiss. Both conditions involve a conflict between bodily form and embodied self-experience. Both can generate serious suffering. Both can involve a demand for bodily alteration as the only adequate resolution. Both depend heavily on the patient’s account, because neither can be confirmed through a standard biomarker.
That last point needs care. Neither BID nor Gender Dysphoria has a routine blood test, scan, or laboratory marker that establishes the diagnosis in the way a tumour, fracture, infection, or endocrine abnormality might be established. Diagnosis is clinical. It depends on history, self-report, pattern recognition, exclusion of alternative explanations, and assessment of distress, impairment, desire, persistence, and risk.
This places both conditions in an uncomfortable area of medicine. Modern clinical authority is strongest when pathology can be made visible: numbers, lesions, imaging, tissue change, measurable dysfunction. Conditions organised around self-report disturb that model. They force medicine to decide how much authority to grant to a patient’s account of their own embodied life.
The comparison therefore blocks one weak argument against BID. The absence of a biomarker cannot, by itself, justify refusal. Medicine already works with diagnostic categories where the patient’s narrative carries decisive clinical weight. The harder problem lies elsewhere.
Institutional history
Gender Dysphoria, under older diagnostic names and newer ones, has a long clinical history. Its current pathways emerged through decades of diagnostic revision, specialist clinics, professional guidance, patient advocacy, political conflict, longitudinal follow-up, and accumulated clinical experience. The field remains contested, especially around assessment standards, age groups, and specific interventions. Even so, medicine has had time to build categories, services, protocols, and professional norms around gender-related care.
BID has only recently entered formal diagnostic classification. It appeared in ICD-11 as Body Integrity Dysphoria, with ICD-11 taking effect globally from 2022. It has no agreed aetiology. It has no evidence-based treatment pathway. It has no professional consensus on appropriate clinical response. Specialist clinics are absent. Large longitudinal cohorts are absent. A widely accepted protocol for managing requests for amputation, paralysis, blindness, or other disabling interventions is absent.
This means the condition is at an early institutional stage. Medicine has named it, coded it, and made it available for discussion within formal classification. It has not yet built the clinical machinery required to treat it in a structured way.
A phenomenological resemblance cannot replace that institutional work. Medicine does not usually move from diagnostic recognition straight to irreversible intervention. It builds evidence, develops assessment standards, tests alternatives, follows outcomes, records harms, and creates professional norms. BID has barely begun that process.
The structure of the intervention
The second difference concerns the requested intervention.
Gender-affirming care is multi-modal. It may include social transition, psychological support, hormonal treatment, voice work, legal changes, and, for some patients, surgery. The pathway is staged. Some elements are reversible or partially reversible. Patients do not all follow the same route. Surgery, where it occurs, sits inside a broader frame of care.
BID-related requests tend to be more direct. A person may ask for the amputation of a specific limb, the severing of a nerve, or the loss of a particular sensory function. The requested change is singular, concrete, and irreversible. Intermediate steps rarely approximate the desired state without crossing the threshold into permanent impairment.
That difference changes the clinical decision. A staged care pathway with reversible early components creates one ethical structure. The deliberate removal or disabling of a healthy body part creates another. Both may arise from self-body conflict, yet the clinician faces different risks, different standards of evidence, and different forms of responsibility.
The public analogy often overheats because it stays at the level of abstraction. At that level, both conditions concern bodily incongruence and bodily modification. Clinical decisions happen at a lower level, where reversibility, staging, alternatives, disability, surgical risk, and evidential support determine what can be justified.
Evidence of benefit
The third difference is the evidence base.
Gender-affirming care has been studied across multiple decades, jurisdictions, and clinical populations. The literature remains politically contested, and disputes continue over methodology, age groups, long-term outcomes, and the interpretation of regret, mental health, and suicidality data. Still, there is a substantial body of clinical research, professional guidance, and follow-up evidence supporting transition-related care for appropriately assessed patients.
The evidence for BID-related amputation is far thinner. The most famous clinical cases remain Robert Smith’s two amputations in Scotland in the late 1990s. Since then, the literature has relied on small case reports, interviews, surveys, and self-reports from people who obtained amputations through self-injury, accidents, or less regulated jurisdictions. Many report reliefs after amputation. Those reports deserve attention, especially because they are consistent across many personal accounts. They remain too limited to carry the same evidential weight as decades of structured clinical research.
Medicine rarely builds a standard of care from scattered cases and retrospective self-report alone, especially when the requested intervention is irreversible and disabling by ordinary clinical standards. The analogy with Gender Dysphoria therefore clarifies what BID lacks: large-scale follow-up, professional consensus, assessment standards, outcome data, and a pathway that can be defended beyond isolated cases.
What the comparison can do
The comparison prevents an easy dismissal. It shows that medicine already works with conditions of self-body conflict without biomarkers. It shows that patient narrative can function as clinical evidence. It shows that irreversible bodily modification can fall within medicine when the request is tied to identity, distress, persistence, and relief.
For BID, this is important because several common objections are too crude. Laboratory invisibility is insufficient as an objection. Identity-related distress is insufficient as an objection. Irreversibility is insufficient as an objection. Medicine already deals with all three in other contexts.
The more defensible objection concerns clinical readiness. BID lacks the infrastructure that would allow medicine to move from recognition to intervention: adequate evidence, agreed assessment standards, follow-up data, professional consensus, risk frameworks, and serious alternatives. That position is stronger than dismissing BID as absurd. It also leaves medicine with a responsibility it often avoids. If BID is a named diagnostic category, then indefinite refusal without research is not a serious long-term answer.
A named condition without a pathway
BID now has a diagnostic name. A named condition can be studied, coded, discussed, challenged, compared, and brought into clinical debate. Naming also creates pressure. Once medicine names a form of suffering, it cannot permanently hide behind ignorance as if no category exists.
The comparison with Gender Dysphoria should therefore be used carefully. It should not be used to demand identical treatment. It should not be avoided because the comparison is politically inconvenient. Its proper use is analytical. It asks why one form of bodily incongruence has become clinically manageable while another remains suspended between recognition and refusal.
Medicine has already accepted that some patients suffer because the body they inhabit and the body they experience as theirs do not coincide. It has accepted that such suffering can require clinical care even when no biomarker exists. It has accepted that bodily modification can, under certain conditions, become part of responsible treatment.
BID tests the limits of those commitments. It asks where the boundary lies between therapeutic bodily modification and impermissible harm. It asks how much evidence is required before medicine can act. It asks whether refusal is grounded in coherent ethical reasoning or in institutional unreadiness.
The central issue is therefore not whether BID and Gender Dysphoria are the same. They are distinct clinical categories with different histories, classifications, evidential bases, and treatment structures. The issue is whether those differences fully justify the radically different responses they receive.
At present, medicine has named BID but has not learned how to handle it. Until that work is done, refusal will continue to look less like a settled ethical conclusion than a temporary substitute for a debate medicine has barely begun.
This essay is adapted from Chapter 1 of my book. The full argument, with empirical findings and complete references, can be found there:
More writing at leandroloriga.com